Transsectoral optimisation of patient safety
Not Applicable
Recruiting
- Conditions
- Insured persons of the participating health insurance funds from the age of 18 who take five or more prescribed drugs and are initially hospitalised by the participating hospitals in an internal medicine ward, geriatrics, visceral surgery, vascular surgery, cardiac and thoracic surgery, orthopaedics as well as trauma surgery, neurology and urology during the study period.
- Registration Number
- DRKS00025485
- Lead Sponsor
- Bergische Universität Wuppertal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 29160
Inclusion Criteria
All insured persons of the participating health insurance companies from the age of 18 who take five or more prescribed drugs and are initially admitted to an internal medicine ward, geriatrics, visceral surgery, vascular surgery, cardiac and thoracic surgery, orthopaedics as well as trauma surgery, neurology and urology by the participating hospitals during the study period are included. Inclusion in the study is consecutive. The study patients will be treated according to the group status of the respective hospital.
Exclusion Criteria
Patients undergoing oncological treatment are excluded, as they are regularly hospitalised due to treatment cycles.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The combined primary endpoint is whether TOP leads to a reduction in the mortality of hospitalised patients with polypharmacy (in hospital and up to 3 months after discharge) and/or the re-hospitalisation rate (within 3 months after discharge).
- Secondary Outcome Measures
Name Time Method Proportion of patients receiving inappropriate prescriptions;<br>Proportion of patients experiencing serious preventable adverse drug reactions in hospital or within 3 months of discharge;<br>Use of emergency outpatient care;<br>General quality of life across diseases;<br>Patient empowerment; <br>Experienced continuity of (pharmaceutical) care;<br>Patient satisfaction with medication information received;<br>Adherence.